ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0322

Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Jeffrey Driban1, Shike Xu2, Timothy McAlington3, John Haran4, Julieann Patarini4 and Bing Lu5, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2University of Connecticut Health Center, Farmington, CT, 3UMass Chan School of Medicine, Arlington, MA, 4UMass Chan Medical School, Worcester, MA, 5UConn Health Center, Newton, MA

Meeting: ACR Convergence 2025

Keywords: Epidemiology, metabolomics, microbiome, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0306–0336) Osteoarthritis – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the gut microbiome and incident OA. Assessing microbiomes can be challenging; however, blood measures (e.g., metabolites) have offered insights into the gut microbiome and its relationship with prevalent OA. Hence, we explored whether blood-based metabolites, reflective of the gut microbiome, relate to incident knee OA during the subsequent 7 years.

Methods: We performed a secondary analysis of a case-cohort study that included 603 participants from the Osteoarthritis Initiative, comprising 237 incident knee OA cases and 366 non-cases from a randomly selected sub-cohort over an 8-year follow-up. Plasma metabolomes were analyzed using liquid chromatography-tandem mass spectrometry. Among the measured metabolites, 47 were previously identified in the literature as microbial metabolites (Rushing BR et al., 2021). We averaged metabolite levels at baseline and year 1 as the exposure and identified incident OA cases as knees with a Kellgren and Lawrence grade ≥2 in subsequent follow-ups. Weighted logistic regression, which accounted for the study design and adjusted for age and gender with and without body mass index (BMI), was used to examine associations between these metabolite concentrations and knee OA incidence. As an exploratory analysis, multiple comparison correction was not applied.

Results: Among the 603 participants, 70% of OA cases (mean [SD] age = 60 [9] years, BMI = 28.6 [4.7] kg/m2), and 55% of non-cases were female (age = 58 [9], BMI = 26.9 [8.0] kg/m2). When adjusting only for age and gender, the upper quartile of 4 metabolites had a statistically significant association with greater odds of incident knee OA (2 had a significant p for trend; Table 1): 3-(3-Hydroxyphenyl)propanoic acid (OR = 1.90, p trend = 0.048), N,N-Dimethylglycine (OR = 1.65, p trend = 0.016), Kynurenic acid (OR = 1.51), N-Acetyl-L-phenylalanine (OR = 1.62). Only 3-(3-Hydroxyphenyl)propanoic acid remained statistically significant after adjusting for BMI (OR = 1.90, Table 2). Three metabolites had evidence suggestive that higher levels related to lower odds of incident OA: Benzoic acid (ORs range = 0.54-0.74), Butyric acid (OR range = 0.63-0.84), and Phenylacetic acid (OR range = 0.66-0.87). Benzoic acid (OR range = 0.62-0.74) and Butyric acid (OR range = 0.66-0.88) remained statistically significant after adjusting for BMI (Table 2). Furthermore, after adjusting for BMI, 10 other metabolites had evidence that higher levels related to lower odds of incident OA, including 3 with a p for trend < 0.05: 4-hydroxyphenylpyruvic acid, Pyruvic acid, and Glucose.

Conclusion: Our results complement a prior cross-sectional analysis using fecal metabolomes, which suggested OA was associated with perturbed pathways, including amino acid metabolism (e.g., glycine, serine, tryptophan, phenylalanine), fatty acid metabolism, dietary polyphenol metabolism, and pyruvate metabolism. Unlike the prior study, we offer longitudinal evidence that these metabolites are altered before the onset of knee OA and may be modifiable risk factors, which can be monitored in blood samples.

Supporting image 1Table 1. Association between microbial metabolites and knee osteoarthritis risk (adjusted for age and gender)

Supporting image 2Table 2. Association between microbial metabolites and knee osteoarthritis risk (adjusted for age, gender, and body mass index)


Disclosures: J. Driban: None; S. Xu: None; T. McAlington: Anika, 2, Grunenthal, 2, Kiniksk, 2, Kolon TissueGene, Inc., 2, Medipost, 2, Novan, 2, Organogenesis, 2, Regeneron, 2, Remedium-Bio, 2, Samumed, 2, Sanofi, 2, Scarcell, 2, Visor, 2; J. Haran: None; J. Patarini: None; B. Lu: None.

To cite this abstract in AMA style:

Driban J, Xu S, McAlington T, Haran J, Patarini J, Lu B. Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/metabolites-reflective-of-the-gut-microbiome-relate-to-future-incident-knee-osteoarthritis-data-from-the-osteoarthritis-initiative/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolites-reflective-of-the-gut-microbiome-relate-to-future-incident-knee-osteoarthritis-data-from-the-osteoarthritis-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology